Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs United States Natural Gas Fund — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while United States Natural Gas Fund trades at $11.2 (market cap $503.45M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 14.9× United States Natural Gas Fund's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and United States Natural Gas Fund for 23 Days on average.
| SYRE | UNG | |
|---|---|---|
Market Cap | $7.52B | $503.45M |
Volume | 1,441,031 | 27,352,527 |
Sector | Health | Commodities - Energy |
52-Week High | $108.92 | $16.90 |
52-Week Low | $22.18 | $9.63 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
UNG trades at $11.41, up 4.49% today, with a bullish technical signal from moving averages. The fund shows strong net income of $65.15M for 2024 despite zero revenue, supported by $593.54M in cash. Recent news highlights natural gas market volatility, with record U.S. production and geopolitical tensions influencing prices.
Outlook: Bullish technicals and solid liquidity offer upside, but reliance on natural gas price swings and zero revenue pose risks. Investors should weigh energy market stability against the fund's cash position and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
